부산대학교 도서관

Nivolumab is one of the new generation anti-cancer drugs used in the treatment of metastatic malignant melanoma, which acts by stimulating the immune system. Unilateral panuveitis was diagnosed in the left eye of 45 years-old man who was on nivolumab treatment for metastatic cutaneous malignant melanoma and presented with anterior uveitis, vitritis and macular edema. Nivolumab treatment was discontinued and two intravitreal dexamethasone implants were administered to left eye 4-months interval. The signs and symptoms were improved within 6 months of follow-up. We aimed to emphasize the need for the careful review of systemic disease history and the drugs used in patients diagnosed with uveitis and to increase awareness of clinicians regarding potential ocular side effects of new generation anti-cancer drugs. [ABSTRACT FROM AUTHOR]